Cargando…

Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment

The purpose of this study was to evaluate the potential of a newly modified cyclodextrin derivative, water-soluble β-cyclodextrin–epichlorohydrin (β-CD), as an effective drug carrier to enhance the poor solubility and bioavailability of galangin (GAL), a poorly water-soluble model drug. In this rega...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbas, Zainab S., Sulaiman, Ghassan M., Jabir, Majid S., Mohammed, Salman A. A., Khan, Riaz A., Mohammed, Hamdoon A., Al-Subaiyel, Amal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318178/
https://www.ncbi.nlm.nih.gov/pubmed/35889394
http://dx.doi.org/10.3390/molecules27144521
_version_ 1784755228422176768
author Abbas, Zainab S.
Sulaiman, Ghassan M.
Jabir, Majid S.
Mohammed, Salman A. A.
Khan, Riaz A.
Mohammed, Hamdoon A.
Al-Subaiyel, Amal
author_facet Abbas, Zainab S.
Sulaiman, Ghassan M.
Jabir, Majid S.
Mohammed, Salman A. A.
Khan, Riaz A.
Mohammed, Hamdoon A.
Al-Subaiyel, Amal
author_sort Abbas, Zainab S.
collection PubMed
description The purpose of this study was to evaluate the potential of a newly modified cyclodextrin derivative, water-soluble β-cyclodextrin–epichlorohydrin (β-CD), as an effective drug carrier to enhance the poor solubility and bioavailability of galangin (GAL), a poorly water-soluble model drug. In this regard, inclusion complexes of GAL/β-CDP were prepared. UV-VIS spectrophotometry, Fourier-transform infrared spectroscopy (FTIR), X-ray crystallography (XRD), zeta potential analysis, particle size analysis, field emission scanning electron microscopy (FESEM), and transmission electron microscopy (TEM) were applied to characterize the synthesized GAL/β-CD. Michigan Cancer Foundation-7 (MCF-7; human breast cancer cells) and rat embryo fibroblast (REF; normal cells) were employed to examine the in vitro cytotoxic effects of GAL/β-CD using various parameters. The dye-based tests of MTT and crystal violet clearly exhibited that GAL/β-CD-treated cells had a reduced proliferation rate, an influence that was not found in the normal cell line. The cells’ death was found to follow apoptotic mechanisms, as revealed by the dye-based test of acridine orange/ethidium bromide (AO/EtBr), with the involvement of the mitochondria via caspase-3-mediated events, as manifested by the Rh 123 test. We also included a mouse model to examine possible in vivo toxic effects of GAL/β-CD. It appears that the inclusion complex does not have a significant influence on normal cells, as indicated by serum levels of kidney and liver enzymatic markers, as well as thymic and splenic mass indices. A similar conclusion was reached on the histological level, as manifested by the absence of pathological alterations in the liver, kidney, thymus, spleen, heart, and lung.
format Online
Article
Text
id pubmed-9318178
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93181782022-07-27 Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment Abbas, Zainab S. Sulaiman, Ghassan M. Jabir, Majid S. Mohammed, Salman A. A. Khan, Riaz A. Mohammed, Hamdoon A. Al-Subaiyel, Amal Molecules Article The purpose of this study was to evaluate the potential of a newly modified cyclodextrin derivative, water-soluble β-cyclodextrin–epichlorohydrin (β-CD), as an effective drug carrier to enhance the poor solubility and bioavailability of galangin (GAL), a poorly water-soluble model drug. In this regard, inclusion complexes of GAL/β-CDP were prepared. UV-VIS spectrophotometry, Fourier-transform infrared spectroscopy (FTIR), X-ray crystallography (XRD), zeta potential analysis, particle size analysis, field emission scanning electron microscopy (FESEM), and transmission electron microscopy (TEM) were applied to characterize the synthesized GAL/β-CD. Michigan Cancer Foundation-7 (MCF-7; human breast cancer cells) and rat embryo fibroblast (REF; normal cells) were employed to examine the in vitro cytotoxic effects of GAL/β-CD using various parameters. The dye-based tests of MTT and crystal violet clearly exhibited that GAL/β-CD-treated cells had a reduced proliferation rate, an influence that was not found in the normal cell line. The cells’ death was found to follow apoptotic mechanisms, as revealed by the dye-based test of acridine orange/ethidium bromide (AO/EtBr), with the involvement of the mitochondria via caspase-3-mediated events, as manifested by the Rh 123 test. We also included a mouse model to examine possible in vivo toxic effects of GAL/β-CD. It appears that the inclusion complex does not have a significant influence on normal cells, as indicated by serum levels of kidney and liver enzymatic markers, as well as thymic and splenic mass indices. A similar conclusion was reached on the histological level, as manifested by the absence of pathological alterations in the liver, kidney, thymus, spleen, heart, and lung. MDPI 2022-07-15 /pmc/articles/PMC9318178/ /pubmed/35889394 http://dx.doi.org/10.3390/molecules27144521 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abbas, Zainab S.
Sulaiman, Ghassan M.
Jabir, Majid S.
Mohammed, Salman A. A.
Khan, Riaz A.
Mohammed, Hamdoon A.
Al-Subaiyel, Amal
Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment
title Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment
title_full Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment
title_fullStr Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment
title_full_unstemmed Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment
title_short Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment
title_sort galangin/β-cyclodextrin inclusion complex as a drug-delivery system for improved solubility and biocompatibility in breast cancer treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318178/
https://www.ncbi.nlm.nih.gov/pubmed/35889394
http://dx.doi.org/10.3390/molecules27144521
work_keys_str_mv AT abbaszainabs galanginbcyclodextrininclusioncomplexasadrugdeliverysystemforimprovedsolubilityandbiocompatibilityinbreastcancertreatment
AT sulaimanghassanm galanginbcyclodextrininclusioncomplexasadrugdeliverysystemforimprovedsolubilityandbiocompatibilityinbreastcancertreatment
AT jabirmajids galanginbcyclodextrininclusioncomplexasadrugdeliverysystemforimprovedsolubilityandbiocompatibilityinbreastcancertreatment
AT mohammedsalmanaa galanginbcyclodextrininclusioncomplexasadrugdeliverysystemforimprovedsolubilityandbiocompatibilityinbreastcancertreatment
AT khanriaza galanginbcyclodextrininclusioncomplexasadrugdeliverysystemforimprovedsolubilityandbiocompatibilityinbreastcancertreatment
AT mohammedhamdoona galanginbcyclodextrininclusioncomplexasadrugdeliverysystemforimprovedsolubilityandbiocompatibilityinbreastcancertreatment
AT alsubaiyelamal galanginbcyclodextrininclusioncomplexasadrugdeliverysystemforimprovedsolubilityandbiocompatibilityinbreastcancertreatment